The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InBracco and ACIST Medical Systems have officially announced the European launch of the ACIST Pro™ Diagnostic System. This next-generation technology is specifically designed for variable-rate contrast management during image-guided cardiovascular procedures. The system recently received the CE Mark clearance, paving the way for its distribution and clinical use across European markets. Building on the success of the previous ACIST CVi® system, the new platform focuses on enhancing precision and patient safety. A primary clinical goal of the ACIST Pro is to reduce contrast media usage and minimize the risk of contrast-induced acute kidney injury. While the launch represents a significant advancement in medical technology, the direct financial impact on public markets remains limited as Bracco is a private entity.